This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Academia Sinica. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Shuen-lu Hung: Innovator in Risk Assessment for Adverse Drug Reactions
Introduction
Shuen-lu Hung is a notable inventor based in Changhua, Taiwan. He has made significant contributions to the field of pharmacogenetics, particularly in the area of predicting adverse drug reactions. His work has implications for patient safety and personalized medicine.
Latest Patents
Hung holds a patent for a method of predicting the risk of patients developing adverse drug reactions, specifically Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The invention identifies the association of the HLA-B*1502 allele with SJS/TEN induced by various drugs, particularly carbamazepine. Additionally, it highlights the role of the HLA-B*5801 allele in allopurinol-induced SJS/TEN and the HLA-B*4601 allele in milder cutaneous reactions. This innovative approach utilizes genetic markers located between the DRB1 and HLA-A regions of specific HLA-B haplotypes for testing.
Career Highlights
Throughout his career, Shuen-lu Hung has worked with prestigious organizations, including Academia Sinica and Pharmigene, Inc. His research has been pivotal in advancing the understanding of genetic factors that contribute to drug reactions.
Collaborations
Hung has collaborated with notable colleagues, including Wen-hung Chung and Yuan-Tsong Chen, to further his research and innovations in the field.
Conclusion
Shuen-lu Hung's contributions to the understanding of adverse drug reactions through genetic markers represent a significant advancement in personalized medicine. His work not only enhances patient safety but also paves the way for future innovations in pharmacogenetics.